Michael Birrer, MD, PhD, professor of medicine in the Division of Hematology-Oncology, and Director of the Comprehensive Cancer Center at the University of Alabama at Birmingham, discusses current data on predicting response to PARP inhibitor therapy in ovarian cancer.
Michael Birrer, MD, PhD, professor of medicine in the Division of Hematology-Oncology, and Director of the Comprehensive Cancer Center at the University of Alabama at Birmingham, discusses current data on predicting response to PARP inhibitor therapy in ovarian cancer.
Birrer says there is a lot of level 1 evidence to show which patients will benefit most from PARP inhibition. It is now known that the patients who will derive the most benefit have germline or somaticBRCA1/2mutations. However, patients who have mutations in other genes within the Fanconi pathway, and possibly patients who have alterations of BRCA1/2 through mechanisms other than mutations, may also benefit from these therapies, Birrer says.
Additionally, patients whose tumors demonstrate a high degree of homologous recombination also benefit from PARP inhibitors, Birrer explains. Still, there are patients who do not demonstrate any of the above and still benefit from PARP inhibition.
Darolutamide Becomes Routine Doublet and Triplet Option in Hormone-Sensitive Prostate Cancer
May 6th 2024Darolutamide has been adopted routinely in clinical practice as a component of both doublet and triplet regimens for the treatment of patients with metastatic hormone-sensitive prostate cancer.
Read More
Responders to UGN-101 Have Positive RFS in Upper Tract Urothelial Cancer
May 5th 2024In patients at 15 centers who had upper tract urothelial cancer, those with no evidence of disease after UGN-101 induction had a 68% rate of 3-year recurrence-free survival, and this outcome did not differ based on tumor status, method of instillation, or treatment intent.
Read More